PTPI Live signals | Maximize Profits with Getagraph.com

SELL 94211 min ago

@ $1.580

Issued: 13 Feb 2024 @ 13:18

Return: -55.83%

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	229 761
Average Volume	975 832
Market Cap	4.80M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.00700 (1.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Bernstein Bruce	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	54 533	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	49 645	Common Stock
2023-12-21	Walker Wayne Remell	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Arnold Mitchell	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
90.56
Last 73 transactions
Buy: 12 778 148 \| Sell: 66 349

Volume Correlation

Long: 0.05 (neutral)

Short: -0.52 (weak negative)

Signal:(57.723) Neutral

Petros Pharmaceuticals, Correlation

10 Most Positive Correlations
ALZN	0.942
AVO	0.941
AMTI	0.922
TCRT	0.913
LYRA	0.91
FATE	0.908
IMCC	0.908
LQDT	0.906
GH	0.905
BIMI	0.903

10 Most Negative Correlations
BNIXU	-0.927
OPNT	-0.924
DVCR	-0.923
STAY	-0.919
AVEO	-0.911
ITMR	-0.907
CIIG	-0.906
VLYPP	-0.904
GLLI	-0.9
ISIG	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Petros Pharmaceuticals, Correlation - Currency/Commodity

0.24
( neutral )

0.10
( neutral )

0.00
( neutral )

0.19
( neutral )

0.00
( neutral )

0.17
( neutral )

Petros Pharmaceuticals, Financials

Annual	2023
Revenue:	$5.82M
Gross Profit:	$908 201 (15.60 %)
EPS:	$-3.75

Q3	2023
Revenue:	$1.67M
Gross Profit:	$1.27M (75.61 %)
EPS:	$-2.15

Q2	2023
Revenue:	$1.99M
Gross Profit:	$1.48M (74.23 %)
EPS:	$-1.200

Q1	2023
Revenue:	$2.52M
Gross Profit:	$1.97M (78.13 %)
EPS:	$-105.04

Financial Reports:

No articles found.

Petros Pharmaceuticals,

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.